ERBB2 and breast cancer: Around 15% of all BC cases show negative expression for all PR, ER and Her2 (i.e. triple negative) and are known to have an aggressive behaviour, a poor response to conventional treatments, and an adverse immunologic profile with a high rate of lymphocytic infiltration, as an indicator of metastasis.5